{"id":8223,"date":"2025-04-16T14:52:04","date_gmt":"2025-04-16T06:52:04","guid":{"rendered":"https:\/\/regask.com\/?p=8223"},"modified":"2025-04-19T03:28:34","modified_gmt":"2025-04-18T19:28:34","slug":"risques-lies-a-la-chaine-dapprovisionnement-des-tarifs-biopharmaceutiques","status":"publish","type":"post","link":"https:\/\/regask.com\/fr\/biopharma-tariff-supply-chain-risks\/","title":{"rendered":"Le minist\u00e8re du Commerce des \u00c9tats-Unis enqu\u00eate sur d\u2019\u00e9ventuelles taxes douani\u00e8res\u2026"},"content":{"rendered":"<div class=\"css-xdofzv\"><\/div>\n<div class=\"css-xdofzv\">\n<div class=\"css-sqb9x\">Le 4 avril 2025, Fierce Pharma a publi\u00e9 un article analysant l&#039;impact potentiel des droits de douane impos\u00e9s par le pr\u00e9sident Donald Trump sur l&#039;industrie biopharmaceutique. Malgr\u00e9 une annonce r\u00e9cente exemptant les produits pharmaceutiques import\u00e9s aux \u00c9tats-Unis de ces droits, l&#039;industrie s&#039;inqui\u00e8te toujours de l&#039;\u00e9ventuelle imposition de droits de douane sur les m\u00e9dicaments import\u00e9s. David Ricks, PDG d&#039;Eli Lilly, commente la situation et souligne les d\u00e9fis et les ajustements potentiels que les entreprises pourraient devoir apporter face \u00e0 ces droits de douane. Cette mise \u00e0 jour vise principalement \u00e0 comprendre les implications du protectionnisme commercial sur le co\u00fbt des m\u00e9dicaments et la gestion de la cha\u00eene d&#039;approvisionnement au sein du secteur biopharmaceutique.<\/div>\n<div id=\"alert__details__read__summary\" class=\"css-1xp4bos\">\n<div class=\"css-1bjy6cq\">\n<ul>\n<li>Le pr\u00e9sident Donald Trump a envisag\u00e9 d\u2019imposer des taxes \u00ab 25% ou plus \u00bb sur les m\u00e9dicaments import\u00e9s, bien qu\u2019une annonce r\u00e9cente ait temporairement exempt\u00e9 les produits pharmaceutiques de ces tarifs.<\/li>\n<li>Eli Lilly a investi massivement dans ses capacit\u00e9s de production aux \u00c9tats-Unis, mais d\u00e9pend \u00e9galement fortement de la production \u00e9trang\u00e8re, notamment en Irlande. L&#039;entreprise craint de devoir absorber les co\u00fbts des droits de douane, ce qui pourrait entra\u00eener des r\u00e9ductions d&#039;effectifs ou des investissements en recherche et d\u00e9veloppement (R&amp;D).<\/li>\n<li>Le calendrier de mise en \u0153uvre des tarifs sur les m\u00e9dicaments reste incertain, avec une p\u00e9riode d\u2019enqu\u00eate maximale de 270 jours mentionn\u00e9e dans l\u2019article 232 de la loi sur l\u2019expansion du commerce.<\/li>\n<li>Le Premier ministre fran\u00e7ais Emmanuel Macron a critiqu\u00e9 les tarifs propos\u00e9s comme \u00e9tant \u00ab brutaux et infond\u00e9s \u00bb, exhortant les pays europ\u00e9ens \u00e0 suspendre leurs investissements aux \u00c9tats-Unis jusqu&#039;\u00e0 de nouvelles \u00e9claircissements.<\/li>\n<li>Les analystes d&#039;UBS sp\u00e9culent que les produits pharmaceutiques pourraient \u00e9ventuellement \u00eatre exclus d&#039;un tarif de base 10%, mais restent prudents quant aux droits potentiels sp\u00e9cifiques \u00e0 l&#039;industrie qui pourraient \u00eatre introduits progressivement.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"css-xdofzv\">\n<div class=\"css-sqb9x\"><span class=\"MuiTypography-root MuiTypography-body14Semi css-v32bg9\" data-color=\"textPrimary\" data-variant=\"body14Semi\">\u00c9valuation<\/span><\/div>\n<div id=\"alert__details__read__insight\" class=\"css-1xp4bos\">\n<div class=\"css-1bjy6cq\">\n<p><strong>Impact:<\/strong>\u00a0Les droits de douane propos\u00e9s pourraient augmenter les co\u00fbts op\u00e9rationnels des entreprises biopharmaceutiques, en particulier celles qui d\u00e9pendent de m\u00e9dicaments ou de composants import\u00e9s. Cela pourrait affecter le prix et la disponibilit\u00e9 des m\u00e9dicaments, avec des r\u00e9percussions potentielles sur les domaines th\u00e9rapeutiques n\u00e9cessitant des m\u00e9dicaments sp\u00e9cialis\u00e9s ou import\u00e9s.<\/p>\n<p><strong>Suivant:<\/strong>\u00a0Les entreprises devraient \u00e9valuer leur cha\u00eene d&#039;approvisionnement afin de d\u00e9celer toute vuln\u00e9rabilit\u00e9 aux droits de douane et envisager d&#039;accro\u00eetre leurs capacit\u00e9s de production nationales. Il est recommand\u00e9 de plaider en faveur de politiques commerciales claires et de se pr\u00e9parer \u00e0 d&#039;\u00e9ventuels ajustements de co\u00fbts en R&amp;D et en personnel. L&#039;accent doit \u00eatre mis sur le maintien de la conformit\u00e9 tout en minimisant l&#039;impact sur le co\u00fbt et la disponibilit\u00e9 des m\u00e9dicaments.<\/p>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Le 4 avril 2025, Fierce Pharma a publi\u00e9 un article analysant l&#039;impact potentiel des droits de douane impos\u00e9s par le pr\u00e9sident Donald Trump sur l&#039;industrie biopharmaceutique. Malgr\u00e9 une annonce r\u00e9cente exemptant les produits pharmaceutiques import\u00e9s aux \u00c9tats-Unis de ces droits, l&#039;industrie s&#039;inqui\u00e8te toujours de l&#039;\u00e9ventuelle imposition de droits de douane sur les m\u00e9dicaments import\u00e9s. Le PDG d&#039;Eli Lilly\u2026<\/p>","protected":false},"author":43,"featured_media":8224,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[527,35],"tags":[625],"class_list":["post-8223","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-united-states-regulations","category-pharma-biotech-latest-insights","tag-tariff-and-tax-regulations"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Trump Tariffs &amp; Pharma: Supply Chain Risks? | RegASK<\/title>\n<meta name=\"description\" content=\"Trump&#039;s tariffs on biopharma: What&#039;s the impact on drug costs &amp; your supply chain? Eli Lilly CEO weighs in. Key insights here.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/fr\/risques-lies-a-la-chaine-dapprovisionnement-des-tarifs-biopharmaceutiques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"US Department of Commerce Investigates Potential\u00a0Tariffs on Imported Pharmaceuticals Impacting Biopharma Industry Summary\" \/>\n<meta property=\"og:description\" content=\"Trump&#039;s tariffs on biopharma: What&#039;s the impact on drug costs &amp; your supply chain? Eli Lilly CEO weighs in. Key insights here.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/fr\/risques-lies-a-la-chaine-dapprovisionnement-des-tarifs-biopharmaceutiques\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-16T06:52:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-18T19:28:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2025\/04\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Reva Ananda\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Reva Ananda\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/\"},\"author\":{\"name\":\"Reva Ananda\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\"},\"headline\":\"US Department of Commerce Investigates Potential\u00a0Tarif&hellip;\",\"datePublished\":\"2025-04-16T06:52:04+00:00\",\"dateModified\":\"2025-04-18T19:28:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/\"},\"wordCount\":353,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png\",\"keywords\":[\"tariff and tax regulations\"],\"articleSection\":[\"United States\",\"Pharma and Biotech\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/\",\"name\":\"Trump Tariffs & Pharma: Supply Chain Risks? | RegASK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png\",\"datePublished\":\"2025-04-16T06:52:04+00:00\",\"dateModified\":\"2025-04-18T19:28:34+00:00\",\"description\":\"Trump's tariffs on biopharma: What's the impact on drug costs & your supply chain? Eli Lilly CEO weighs in. Key insights here.\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png\",\"width\":800,\"height\":600,\"caption\":\"Us Department Commerce Investigates Tariffs Imported Pharmaceuticals Biopharma Industry\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\",\"name\":\"RegASK\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"width\":401,\"height\":401,\"caption\":\"RegASK\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RegASKRegulatoryAffairs\\\/\",\"https:\\\/\\\/x.com\\\/ASKRegASK\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/RegASK\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@RegASK\",\"https:\\\/\\\/www.crunchbase.com\\\/organization\\\/regask\",\"https:\\\/\\\/www.bloomberg.com\\\/profile\\\/company\\\/1691237D:SP\",\"https:\\\/\\\/pitchbook.com\\\/profiles\\\/company\\\/265004-02\",\"https:\\\/\\\/www.cbinsights.com\\\/company\\\/RegASK\",\"https:\\\/\\\/vimeo.com\\\/RegASK\"],\"legalName\":\"RegASK PTE. LTD.\",\"foundingDate\":\"2018\",\"slogan\":\"Empowering Smarter Regulatory Decisions\",\"description\":\"Agentic AI regulatory intelligence and workflow orchestration platform for Life Sciences and Consumer Products. RegASK combines vertical LLMs, multi-agent AI architecture, and a global community of 1,800+ subject matter experts to deliver regulatory horizon scanning, impact analysis, compliance workflow automation, and audit-ready outputs across 160+ countries.\",\"areaServed\":\"Worldwide\",\"founder\":{\"@type\":\"Person\",\"name\":\"Caroline Shleifer\",\"jobTitle\":\"Founder & CEO\"},\"address\":{\"@type\":\"PostalAddress\",\"streetAddress\":\"79 Science Park Drive, #06-01, Cintech IV\",\"addressLocality\":\"Singapore\",\"postalCode\":\"118264\",\"addressCountry\":\"SG\"},\"contactPoint\":{\"@type\":\"ContactPoint\",\"telephone\":\"+65 6817 6290\",\"contactType\":\"customer service\",\"availableLanguage\":[\"English\",\"French\",\"Japanese\",\"Spanish\",\"Chinese\",\"German\"]},\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":50,\"maxValue\":100},\"knowsAbout\":[\"Regulatory Intelligence\",\"Regulatory Compliance\",\"Regulatory Affairs\",\"Workflow Orchestration\",\"Life Sciences Regulation\",\"Consumer Products Regulation\",\"AI-Driven Compliance\"],\"hasCertification\":[{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 42001:2023\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27001:2022\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27701\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27018:2019\"},{\"@type\":\"Certification\",\"name\":\"SOC 2 Type II\"}]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\",\"name\":\"Reva Ananda\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Droits de douane impos\u00e9s par Trump et produits pharmaceutiques\u00a0: des risques pour la cha\u00eene d&#039;approvisionnement\u00a0? | RegASK","description":"Droits de douane impos\u00e9s par Trump sur les produits biopharmaceutiques\u00a0: quel impact sur le co\u00fbt des m\u00e9dicaments et votre cha\u00eene d&#039;approvisionnement\u00a0? Le PDG d&#039;Eli Lilly donne son avis. Points cl\u00e9s ici.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/fr\/risques-lies-a-la-chaine-dapprovisionnement-des-tarifs-biopharmaceutiques\/","og_locale":"fr_FR","og_type":"article","og_title":"US Department of Commerce Investigates Potential\u00a0Tariffs on Imported Pharmaceuticals Impacting Biopharma Industry Summary","og_description":"Trump's tariffs on biopharma: What's the impact on drug costs & your supply chain? Eli Lilly CEO weighs in. Key insights here.","og_url":"https:\/\/regask.com\/fr\/risques-lies-a-la-chaine-dapprovisionnement-des-tarifs-biopharmaceutiques\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2025-04-16T06:52:04+00:00","article_modified_time":"2025-04-18T19:28:34+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/04\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png","type":"image\/png"}],"author":"Reva Ananda","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Reva Ananda","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/#article","isPartOf":{"@id":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/"},"author":{"name":"Reva Ananda","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926"},"headline":"US Department of Commerce Investigates Potential\u00a0Tarif&hellip;","datePublished":"2025-04-16T06:52:04+00:00","dateModified":"2025-04-18T19:28:34+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/"},"wordCount":353,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/04\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png","keywords":["tariff and tax regulations"],"articleSection":["United States","Pharma and Biotech"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/","url":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/","name":"Droits de douane impos\u00e9s par Trump et produits pharmaceutiques\u00a0: des risques pour la cha\u00eene d&#039;approvisionnement\u00a0? | RegASK","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/04\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png","datePublished":"2025-04-16T06:52:04+00:00","dateModified":"2025-04-18T19:28:34+00:00","description":"Droits de douane impos\u00e9s par Trump sur les produits biopharmaceutiques\u00a0: quel impact sur le co\u00fbt des m\u00e9dicaments et votre cha\u00eene d&#039;approvisionnement\u00a0? Le PDG d&#039;Eli Lilly donne son avis. Points cl\u00e9s ici.","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/04\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/04\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png","width":800,"height":600,"caption":"Us Department Commerce Investigates Tariffs Imported Pharmaceuticals Biopharma Industry"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Le syst\u00e8me d&#039;exploitation d&#039;IA r\u00e9glementaire pour les \u00e9quipes performantes","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/regask.com\/#organization","name":"RegASK","url":"https:\/\/regask.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","width":401,"height":401,"caption":"RegASK"},"image":{"@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","https:\/\/x.com\/ASKRegASK","https:\/\/www.linkedin.com\/company\/RegASK\/","https:\/\/www.youtube.com\/@RegASK","https:\/\/www.crunchbase.com\/organization\/regask","https:\/\/www.bloomberg.com\/profile\/company\/1691237D:SP","https:\/\/pitchbook.com\/profiles\/company\/265004-02","https:\/\/www.cbinsights.com\/company\/RegASK","https:\/\/vimeo.com\/RegASK"],"legalName":"RegASK PTE. LTD.","foundingDate":"2018","slogan":"Empowering Smarter Regulatory Decisions","description":"Plateforme d&#039;intelligence artificielle multi-agents pour la veille r\u00e9glementaire et l&#039;orchestration des flux de travail dans le secteur des sciences de la vie et des produits de consommation. RegASK combine des LLM verticaux, une architecture d&#039;IA multi-agents et une communaut\u00e9 mondiale de plus de 1\u00a0800 experts pour fournir une veille r\u00e9glementaire, une analyse d&#039;impact, l&#039;automatisation des processus de conformit\u00e9 et des r\u00e9sultats pr\u00eats pour l&#039;audit dans plus de 160 pays.","areaServed":"Worldwide","founder":{"@type":"Person","name":"Caroline Shleifer","jobTitle":"Founder & CEO"},"address":{"@type":"PostalAddress","streetAddress":"79 Science Park Drive, #06-01, Cintech IV","addressLocality":"Singapore","postalCode":"118264","addressCountry":"SG"},"contactPoint":{"@type":"ContactPoint","telephone":"+65 6817 6290","contactType":"customer service","availableLanguage":["English","French","Japanese","Spanish","Chinese","German"]},"numberOfEmployees":{"@type":"QuantitativeValue","minValue":50,"maxValue":100},"knowsAbout":["Regulatory Intelligence","Regulatory Compliance","Regulatory Affairs","Workflow Orchestration","Life Sciences Regulation","Consumer Products Regulation","AI-Driven Compliance"],"hasCertification":[{"@type":"Certification","name":"ISO\/IEC 42001:2023"},{"@type":"Certification","name":"ISO\/IEC 27001:2022"},{"@type":"Certification","name":"ISO\/IEC 27701"},{"@type":"Certification","name":"ISO\/IEC 27018:2019"},{"@type":"Certification","name":"SOC 2 Type II"}]},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926","name":"Reva Ananda"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/8223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/comments?post=8223"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/8223\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media\/8224"}],"wp:attachment":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media?parent=8223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/categories?post=8223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/tags?post=8223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}